Abstract:Background & aims Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic metabolic liver disease and ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). However, the molecular mechanisms underlying steatosis-to-NASH progression remain incompletely understood. Methods In the present study, we investigated the profiling changes of MicroRNAs and identified miR-145a-5p as an important checkpoint in this process. In vivo loss-of-function and gain-of-function studies were performed to explore the role of miR-145a-5p and Nr4a2 in NASH progression. RNA-Sequencing and bioinformatic analysis were used to investigate the target of miR-145a-5p. Results Suppression of miR-145a-5p in the liver activated hepatic inflammation, liver injury and fibrosis in steatotic mice, whereas its restoration markedly attenuated diet-induced NASH pathogenesis. Mechanistically, miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to inhibit the expression of NASH-associated genes. Similarly, Nr4a2 overexpression promoted steatosis-to-NASH progression while liver-specific Nr4a2 knockout mice were protected from diet-induced NASH. Of potential clinical significance, the miR-145a-5p/Nr4a2 regulatory axis was also confirmed in human primary hepatocytes. Besides, expression level of miR-145a-5p was reduced and Nr4a2 was increased in the livers of NASH patients. Their expression levels were significantly correlated with hepatic pathological features. Conclusions Our findings highlight the role of miR-145a-5p/Nr4a2 regulatory axis in steatosis-to-NASH progression, suggesting that either supplementation of miR-145a-5p or pharmacological inhibition of Nr4a2 in hepatocytes may provide a promising therapeutic approach for treating NASH. Impact and implications Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic liver disease ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Unfortunately, there are currently no approved drugs for NASH. Our current study identified miR-145a-5p as a novel regulator that inhibits steatosis-to-NASH progression. We found that miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to suppress the expression of NASH-associated genes. The differentially expression of miR-145a-5p and Nr4a2 was further confirmed in patients with NASH, raising the possibility that supplementation of miR-145a-5p or suppression of Nr4a2 in hepatocytes might provide novel strategies for treating NASH.

MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in miceResearch in context

Targeting Hepatic Mir-221/222 for Therapeutic Intervention of Nonalcoholic Steatohepatitis in Mice

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice.

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2

Effect of Mir-146 Targeted Hdmcp Up Regulation in the Pathogenesis of Nonalcoholic Steatohepatitis

Circrna Expression Pattern And Circrna-Mirna-Mrna Network In The Pathogenesis Of Nonalcoholic Steatohepatitis

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

Down-regulation of Mir-144 Elicits Proinflammatory Cytokine Production by Targeting Toll-Like Receptor 2 in Nonalcoholic Steatohepatitis of High-Fat-diet-induced Metabolic Syndrome E3 Rats.

Mir-488-5p Mitigates Hepatic Stellate Cell Activation and Hepatic Fibrosis Via Suppressing TET3 Expression

Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH

LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis